Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2006-04-11
2006-04-11
Murphy, Joseph (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C435S006120, C435S069100, C530S300000, C530S350000
Reexamination Certificate
active
07026444
ABSTRACT:
The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the petpide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.
REFERENCES:
patent: 5688653 (1997-11-01), Ulrich et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 5976832 (1999-11-01), Hitomi et al.
patent: 0731166 (1996-09-01), None
patent: 731166 (1996-09-01), None
patent: WO 9739121 (1997-10-01), None
patent: WO 9739125 (1997-10-01), None
Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412.
Borchelt, D. R., et al. (1996). Familial Alzheimer's Disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratioin vitroandin vivo. Neuron 17: 1005-1013.
Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6):1699-1712.
Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15 (12):1835-1842.
Cai, X-D., et al. (1993). Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259: 514-516.
Citron, M., et al. (1997). Mutant presenilins of Alzheimer's Disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nature Medicine 3(1):67-72.
Dell'Angelica, E.C., et al. (1994). Primary structure and binding properties of calgranulin C, a novel s100-like calcium-binding protein from pig granulocytes. J. Biol. Chem. 269: 28929-28936.
Fahey, T., et al. (1991). Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 50: 308-313.
Fu, M-X., et al. (1996). The advanced glycation end product, Nε-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986.
Giardino, I., et al. (1994). Nonenzymatic glycosylationin vitroand in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117.
Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for vascular diseases. Science 272: 689-693.
Hofmann, M. A., et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell 97:889-901.
Hori, O., et al. (1995). The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin J. Biol. Chem. 270: 25752-25761.
Khoury, J. E., et al., (1994). Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J. Biol. Chem. 269: 10197-10200.
Kuo, Y-M., et al. (1996). Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer Disease brains. J. Biol. Chem. 271(8): 4077-4081.
Lander, H. M., et al. (1997). Activation of the receptor for advanced glycation end products triggers a p21rasdependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272: 17810-17814.
Ledesma, M. D., et al. (1994). Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 269(34):21614-21619.
Li, J. and A.M. Schmidt (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272: 16498-16506.
Lorenzo, A. and B.A. Yanker (1994). β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Nat. Acad. Sci. USA 91: 12243-12247.
Mattson, M. P. and Y. Goodman (1995). Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676: 219-224.
Miyata, T., et al. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-β2 Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J. Clin. Invest. 98: 1088-1094.
Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143(6): 1649-1656.
Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004.
Palinski, W., et al. (1995). Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscl. Thromb. and Vasc. Biol. 15(5): 571-582.
Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4: 1025-1031.
Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079.
Reddy, S., et al. (1995). Nε-(Carboxymethyl) lysine is a dominant advanced glycatoin end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878.
Renard, C., et al. (1997). Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharm. 52: 54-62.
Ritthaler, U., et al. (1995). Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease, Am. J. Pathol. 146: 688-694.
Roher, A. E., et al. (1996). Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's Disease. J. Biol. Chem. 271 (34): 20631-20635.
Schleicher, E. D., et al. (1997). Increased accumulation of the glycoxidation product Nε-(carboxymethyl) lysine in human tissues in diabetes and aging. J. Clin. Invest. 99: 457-468.
Schmidt, A. M., et al. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J. Clin. Invest. 96: 1395-1403.
Schmidt, A. M., et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Nat'l Acad. Sci. USA 91: 8807-8811.
Schmidt, A. M., et al. (1992). Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267: 14987-14997.
Schmidt, A. M., et al. (1994). Cellular receptors for advanced glycation end products. Arterioscler. Thromb. 14:1521-1528.
Schmidt, A. M., et al. (1995). The dark side of glucose. (News and Views). Nature Medicine 1: 1002-1004.
Schmidt, A. M., et al. (1993). Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 92: 2155-2168.
Schmidt, A. M., et al. (1997). The V-domain of receptor for advanced glycation endproducts (RAGE) mediates binding of AGEs: a novel target
Schmidt Ann Marie
Stern David
Cooper & Dunham LLP
Emch Gregory S.
Murphy Joseph
The Trustees of Columbia University in the City of New York
White, Esq. John P.
LandOfFree
Extracellular novel RAGE binding protein (EN-RAGE) and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Extracellular novel RAGE binding protein (EN-RAGE) and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extracellular novel RAGE binding protein (EN-RAGE) and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3568373